Evonik Health Care vs ReciBioPharm: CDMO Comparison
How does Evonik Health Care compare to ReciBioPharm for mRNA/LNP manufacturing?
Side-by-side comparison of Evonik Health Care and ReciBioPharm on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Evonik Health Care has FDA inspections on record (2); ReciBioPharm does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
On a 13-modality CDMO landscape, both Evonik Health Care and ReciBioPharm qualify as mRNA/LNP manufacturers; ReciBioPharm carries the higher composite Signal Score for mRNA/LNP programs in this comparison.
What to evaluate for mRNA/LNP programs
Both Evonik Health Care and ReciBioPharm qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
Frequently asked: Evonik Health Care vs ReciBioPharm
How does Evonik Health Care compare to ReciBioPharm for mRNA/LNP manufacturing?
On CDMO Signal's composite Signal Score, Evonik Health Care is 82/100 and ReciBioPharm is 83/100; Evonik Health Care has 2 FDA inspections on record vs 0 for ReciBioPharm; European coverage is 2 active EMA+MHRA certificates for Evonik Health Care vs 3 for ReciBioPharm. Both are tracked in the CDMO Signal directory as mRNA/LNP CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Evonik Health Care or ReciBioPharm?
Both Evonik Health Care and ReciBioPharm maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Evonik Health Care has 2 FDA inspections on record; ReciBioPharm has 0.
How do Evonik Health Care and ReciBioPharm compare on European GMP coverage?
Evonik Health Care holds 0 active EMA GMP certificates and 2 MHRA / UK certificates. ReciBioPharm holds 0 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for mRNA/LNP manufacturing — Evonik Health Care or ReciBioPharm?
Both Evonik Health Care and ReciBioPharm are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Evonik Health Care carries a Signal Score of 82/100 and ReciBioPharm carries 83/100 — essentially tied for ReciBioPharm. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →